0 3 The the DT 4 16 Epstein-Barr epstein-barr JJ 17 22 virus virus NN 23 34 oncoprotein oncoprotein NN 35 41 latent latent JJ 42 50 membrane membrane NN 51 58 protein protein NN 59 60 1 1 CD 61 68 engages engage VBZ 69 72 the the DT 73 78 tumor tumor NN 79 87 necrosis necrosis NN 88 94 factor factor NN 95 114 receptor-associated receptor-associated JJ 115 123 proteins protein NNS 124 129 TRADD TRADD NNP 130 133 and and CC 134 154 receptor-interacting receptor-interacting JJ 155 162 protein protein NN 163 164 ( ( ( 164 167 RIP RIP NNP 167 168 ) ) ) 169 172 but but CC 173 177 does do VBZ 178 181 not not RB 182 188 induce induce VB 189 198 apoptosis apoptosis NN 199 201 or or CC 202 209 require require VB 210 213 RIP RIP NNP 214 217 for for IN 218 227 NF-kappaB NF-kappaB NNP 228 238 activation activation NN 238 239 . . . 241 242 A a DT 243 247 site site NN 248 250 in in IN 251 254 the the DT 255 267 Epstein-Barr epstein-barr JJ 268 273 virus virus NN 274 275 ( ( ( 275 278 EBV EBV NNP 278 279 ) ) ) 280 292 transforming transform VBG 293 300 protein protein NN 301 305 LMP1 lmp1 NN 306 310 that that WDT 311 325 constitutively constitutively RB 326 336 associates associate VBZ 337 341 with with IN 342 345 the the DT 346 351 tumor tumor NN 352 360 necrosis necrosis NN 361 367 factor factor NN 368 376 receptor receptor NN 377 378 1 1 CD 379 380 ( ( ( 380 397 TNFR1)-associated tnfr1)-associated JJ 398 403 death death NN 404 410 domain domain NN 411 418 protein protein NN 419 424 TRADD tradd NN 425 427 to to TO 428 435 mediate mediate VB 436 445 NF-kappaB NF-kappaB NNP 446 449 and and CC 450 455 c-Jun c-jun NN 456 466 N-terminal n-terminal JJ 467 473 kinase kinase NNP 474 484 activation activation NN 485 487 is be VBZ 488 496 critical critical JJ 497 500 for for IN 501 510 long-term long-term JJ 511 525 lymphoblastoid lymphoblastoid JJ 526 530 cell cell NN 531 544 proliferation proliferation NN 544 545 . . . 546 548 We we PRP 549 552 now now RB 553 557 find find VBP 558 562 that that IN 563 567 LMP1 lmp1 NN 568 577 signaling signaling NN 578 585 through through IN 586 591 TRADD TRADD NNP 592 599 differs differ VBZ 600 604 from from IN 605 610 TNFR1 tnfr1 NN 611 620 signaling signaling NN 621 628 through through IN 629 634 TRADD TRADD NNP 634 635 . . . 636 640 LMP1 LMP1 NNP 641 646 needs need VBZ 647 651 only only RB 652 654 11 11 CD 655 660 amino amino NN 661 666 acids acid NNS 667 669 to to TO 670 678 activate activate VB 679 688 NF-kappaB NF-kappaB NNP 689 691 or or CC 692 701 synergize synergize VB 702 706 with with IN 707 712 TRADD TRADD NNP 713 715 in in IN 716 725 NF-kappaB NF-kappaB NNP 726 736 activation activation NN 736 737 , , , 738 743 while while IN 744 749 TNFR1 TNFR1 NNP 750 758 requires require VBZ 759 772 approximately approximately RB 773 775 70 70 CD 776 784 residues residue NNS 784 785 . . . 786 793 Further further RB 793 794 , , , 795 799 LMP1 LMP1 NNP 800 804 does do VBZ 805 808 not not RB 809 816 require require VB 817 822 TRADD TRADD NNP 823 831 residues residue NNS 832 835 294 294 CD 836 838 to to TO 839 842 312 312 CD 843 846 for for IN 847 856 NF-kappaB NF-kappaB NNP 857 867 activation activation NN 867 868 , , , 869 874 while while IN 875 880 TNFR1 TNFR1 NNP 881 889 requires require VBZ 890 895 TRADD TRADD NNP 896 904 residues residue NNS 905 908 296 296 CD 909 911 to to TO 912 915 302 302 CD 915 916 . . . 917 921 LMP1 LMP1 NNP 922 924 is be VBZ 925 934 partially partially RB 935 942 blocked block VBN 943 946 for for IN 947 956 NF-kappaB NF-kappaB NNP 957 967 activation activation NN 968 970 by by IN 971 972 a a DT 973 978 TRADD TRADD NNP 979 985 mutant mutant NN 986 996 consisting consist VBG 997 999 of of IN 1000 1008 residues residue NNS 1009 1012 122 122 CD 1013 1015 to to TO 1016 1019 293 293 CD 1019 1020 . . . 1021 1027 Unlike unlike IN 1028 1033 TNFR1 TNFR1 NNP 1033 1034 , , , 1035 1039 LMP1 LMP1 NNP 1040 1043 can can MD 1044 1052 interact interact VB 1053 1061 directly directly RB 1062 1066 with with IN 1067 1087 receptor-interacting receptor-interacting JJ 1088 1095 protein protein NN 1096 1097 ( ( ( 1097 1100 RIP RIP NNP 1100 1101 ) ) ) 1102 1105 and and CC 1106 1112 stably stably RB 1113 1123 associates associate VBZ 1124 1128 with with IN 1129 1132 RIP RIP NNP 1133 1135 in in IN 1136 1151 EBV-transformed ebv-transformed JJ 1152 1166 lymphoblastoid lymphoblastoid JJ 1167 1171 cell cell NN 1172 1177 lines line NNS 1177 1178 . . . 1179 1191 Surprisingly surprisingly RB 1191 1192 , , , 1193 1197 LMP1 LMP1 NNP 1198 1202 does do VBZ 1203 1206 not not RB 1207 1214 require require VB 1215 1218 RIP RIP NNP 1219 1222 for for IN 1223 1232 NF-kappaB NF-kappaB NNP 1233 1243 activation activation NN 1243 1244 . . . 1245 1252 Despite despite IN 1253 1265 constitutive constitutive JJ 1266 1277 association association NN 1278 1282 with with IN 1283 1288 TRADD TRADD NNP 1289 1291 or or CC 1292 1295 RIP RIP NNP 1295 1296 , , , 1297 1301 LMP1 LMP1 NNP 1302 1306 does do VBZ 1307 1310 not not RB 1311 1317 induce induce VB 1318 1327 apoptosis apoptosis NN 1328 1330 in in IN 1331 1343 EBV-negative ebv-negative JJ 1344 1351 Burkitt Burkitt NNP 1352 1360 lymphoma lymphoma NN 1361 1363 or or CC 1364 1369 human human JJ 1370 1379 embryonic embryonic JJ 1380 1386 kidney kidney NN 1387 1390 293 293 CD 1391 1396 cells cell NNS 1396 1397 . . . 1398 1403 These these DT 1404 1411 results result NNS 1412 1415 add add VBP 1416 1417 a a DT 1418 1427 different different JJ 1428 1439 perspective perspective NN 1440 1442 to to TO 1443 1446 the the DT 1447 1456 molecular molecular JJ 1457 1469 interactions interaction NNS 1470 1477 through through IN 1478 1483 which which WDT 1484 1488 LMP1 LMP1 NNP 1488 1489 , , , 1490 1495 TRADD TRADD NNP 1495 1496 , , , 1497 1500 and and CC 1501 1504 RIP RIP NNP 1505 1516 participate participate VBP 1517 1519 in in IN 1520 1532 B-lymphocyte B-lymphocyte NNP 1533 1543 activation activation NN 1544 1547 and and CC 1548 1554 growth growth NN 1554 1555 . . .